Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Leukemia Research
|
January 1, 2021
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients
Giovanni Marconi, Stefano De Polo, Giovanni Martinelli, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
The Lancet. Oncology
|
December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood Cancer Journal
|
June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
European Journal of Haematology
|
March 8, 2020
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia
Giovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, et al.
Blood
|
December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
Cathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Leukemia Research
|
January 1, 2021
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients
Giovanni Marconi, Stefano De Polo, Giovanni Martinelli, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 3, 2024
Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Nature Communications
|
January 3, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
Omar Nadeem, Michelle P Aranha, Robert Redd, et al.
The Lancet. Oncology
|
December 17, 2022
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
Roberto Mina, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Blood Cancer Journal
|
June 7, 2024
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, et al.
European Journal of Haematology
|
March 8, 2020
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia
Giovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, et al.
Blood
|
December 18, 2025
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
Cathelijne Fokkema, Luca Bertamini, Madelon M E de Jong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Luca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.
Page
of 3